This Week in Cardiology Jan 12 2024 This Week in Cardiology
5 snips
Jan 12, 2024 Topics in this podcast include GLP-1s and BaroStim Neo, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statin use. The podcast also discusses listener feedback on obesity, the tension between regulation and innovation in cardiology, evidence generation, and the efficacy of different medications for heart conditions.
AI Snips
Chapters
Transcript
Episode notes
Listener Pushback On Obesity Framing
- John Mandrola recounts listener feedback accusing him of old-fashioned framing of obesity and acknowledging complexity in discussing weight.
- He commits to remembering comments that obesity is genetic and to avoid moralizing when advising patients.
Reviewer Explains FDA's Broader View
- An anonymous electrophysiologist explained FDA considers the totality of evidence and pushes device adoption despite imperfect RCT data.
- They argued FDA's role partly corrects past delays in device availability and shifts rigorous evaluation to postmarket studies.
Clinicians Drive Overuse Of Weakly Supported Devices
- Mandrola argues clinicians—not just regulators—drive overuse of costly, low-value technologies once approved.
- He advocates tying reimbursement to evidence generation to avoid premature widespread adoption.